Jiangsu Hengrui Pharmaceuticals Co Ltd

(a) Capital structure and liquidity are characterized by a highly conservative balance sheet. The company reports a current ratio of 8.08, indicating substantial short-term liquidity coverage relative to current liabilities. Long-term debt is minimal at CNY 74.2 million against total equity of CNY 61.3 billion, resulting in a debt-to-equity ratio of 0.0. Despite the strong liquidity position, the risk assessment flags medium liquidity risk, noting that net cash is negative after subtracting total debt, which suggests that while current assets are high, the net cash position relative to total debt obligations requires monitoring.

(b) Profitability metrics demonstrate strong operational efficiency. The company generates a gross profit of CNY 27.3 billion on revenue of CNY 31.6 billion, implying a gross margin of approximately 86%. Operating income stands at CNY 8.8 billion, leading to a net income of CNY 7.7 billion. Return on equity is 12.58%, and return on assets is 11.04%, indicating effective utilization of both shareholder equity and total assets to generate profits. These returns are supported by robust operating cash flow of CNY 11.2 billion, which exceeds net income, highlighting high earnings quality.

Analysts project 76.5% upside to a mean price target of 96.72, reflecting strong consensus buy ratings.

The company maintains a zero debt-to-equity ratio, providing a pristine balance sheet compared to the cohort median.

Medium liquidity risk flags potential challenges in trading volume or market depth for the stock.

Low dilution risk indicates limited immediate threat from share issuance, though growth funding needs remain.

Revenue ¥31.63B, +13,0% YoY; Operating income +22,5% YoY.

• ▍Revenue ¥31.63B, +13,0% YoY
• ▍Operating income +22,5% YoY
• ▍Net income +21,7% YoY
• ▍Free cash flow +8,8% YoY
• ▍Net margin 24.4%